Featured

Featured posts

Humiragate: AbbVie’s desperate attempts to keep its monopoly

A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...

Medicines Law & Policy’s director, Ellen ’t Hoen, receives high Netherlands honour for her...

Ellen 't Hoen has been appointed Officer of the Order of Oranje-Nassau, a royal award which recognises those who merit particular appreciation from society...

Covid-19 and the comeback of compulsory licensing

The Covid-19 outbreak raises many questions, including some we can answer using experiences gained in previous disease outbreaks. Here is one: how to deal...

Gilead’s sofosbuvir patent in India – options for global access to new hepatitis C...

Earlier this month the US pharmaceutical company Gilead obtained a patent in India for sofosbuvir, part of a treatment of hepatitis C that became...

Independent Panel for Pandemic Preparedness and Response: Uneven access to vaccination is pre-eminent problem

The Independent Panel for Pandemic Preparedness and Response (IPPPR) today released its findings in a report titled “Covid-19: Make it the last pandemic,” laying...

BMJ Commentary: Overriding drug and medical technology patents for pandemic recovery: a legitimate move...

Interest in the use of compulsory licensing is making a comeback in high-income countries in response to concerns about access to Covid-19 vaccines and...

Urgent collective action to meet the challenge of this pandemic crisis: a coronavirus related...

The Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, first described the present coronavirus (COVID-19) outbreak as a pandemic on the 11th...

Ensuring that intellectual property rights aren’t a barrier to scaling-up: the remarkable example of...

This week various international bodies are tackling different challenges in meeting the urgent problem of scaling-up manufacture of and access to vaccines for Covid-19....

Time to put a stop to the abuse of orphan drug regulation- the latest...

Today, the Dutch Medical Journal (Nederlands Tijdschrift voor Geneeskunde) reported on the case of lutetium-octreotaat, a cancer drug developed by researchers in the Dutch...

Never say never – Why the High Income Countries that opted-out from the Art....

To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...